Improve pharmacovigilance responses and drug risk–benefit analyses with efficient, accurate, comprehensive and compliant adverse event capture, assessment and reporting.
Increasing PV search efficiency and accuracy translates to better drug safety and patient outcomes. Conscious of the workload and compliance challenges involved in the crucial detection of drug safety signals, Elsevier continually develops solutions to help. With our R&D Solutions for PV, you can centralize information management and reporting, easily access key data sources, and automate adverse event detection.
Leverage our dedicated R&D Solutions for PV to:
Generate information search strategies that have high recall and precision
Quickly detect adverse event information across various types of scientific literature
Easily search FDA/EMA drug approval and comparative drug safety data and FAERS reports
Automate and centralize information management with a GxP-compliant pharmacovigilance workflow management tool
Quickly generate audit-ready reports
Track progress and manage the workload of literature review staff members
Enhancing key PV Solutions to boost the efficiency of drug safety workflows
See our exclusive webinar focusing on our 2018 enhancements to Embase, PharmaPendium and QUOSA PV. Discover what’s changed and how it improves the monitoring of relevant databases, assessment of captured information, and supervision of the workflow.
Thousands of pharmacovigilance and drug safety teams at pharmaceutical companies rely on Elsevier’s R&D Solutions and services. We have focused on providing comprehensive coverage of drug safety data sources and alleviating challenges with pharmacovigilance processes.
Promote efficiency and organizational compliance. QUOSA centralizes the discovery of adverse event information from multiple sources and automates information monitoring and triage in a scalable, GxP-compliant environment.
Make more informed decisions on drug safety and efficacy, risk, and study design. PharmaPendium delivers comparative drug interaction data and facilitates searches of FDA and EMA drug approval document sources, including FAERS.
Improve monitoring of biomedical literature for adverse events. Embase is the world’s most comprehensive database of peer-reviewed and grey biomedical literature. It includes crucial non-English content and offers unique support for search design.
Let informatics and analytics experts support your drug safety goals. Our Professional Services team can streamline adverse event and safety signal detection by validating search strategies and implementing solutions for literature triage and review.
What is the key to more efficient risk–benefit analysis?
A strong drug safety strategy with efficient risk–benefit analysis is a commitment to patient safety and a healthy drug life cycle. This new white paper assesses the five steps to follow in building an efficient, accurate and compliant strategy for capturing and reviewing adverse event information from the biomedical literature.
This new application note gives a step-by-step example of building a search for adverse drug events using Embase’s PV Wizard. The method described can be applied to any pharmacovigilance-focused search of the biomedical literature.
See how our workflow management tool promotes efficient and compliant pharmacovigilance. QUOSA helps you automate monitoring of relevant databases, streamline assessment of captured information, and more easily supervise the workflow.
Compliance is critical in the highly regulated world of pharmacovigilance. Find out how Elsevier’s Professional Services team helped one pharmaceutical company improve the compliance of their literature screening.
The FDA and EMA expect 100% of adverse drug reactions to be found in the literature monitoring process, so your search formula must be designed to achieve perfect recall. At the same time, though, you want to minimize the number of irrelevant records retrieved in order to maintain efficiency. Read the white paper
Pharmacovigilance requires the right tools
Literature monitoring can help you report adverse events fast only if your process is up-to-date. With more data today than ever before — and more adverse events reported — monitoring has become more challenging. But the right solutions can help you.